Share
.webp)
.webp)
.webp)
.webp)
William E. Evans
BioSkryb Genomics, a pioneer in single-cell and ultra-low-input multiomic solutions, has appointed William E. Evans, Pharm.D. as its Chief Executive Officer.
Dr. Evans has served on BioSkryb’s Board of Directors and as Chair of its Scientific Advisory Board since 2019. He succeeds Suresh Pisharody, who has departed the company to pursue other opportunities.
Dr. Evans brings four decades of leadership in pediatric oncology research, pharmacogenomics, and translational research to his new role. He joined St. Jude Children’s Research Hospital in 1976 and later founded and chaired its Pharmaceutical Sciences Department from 1986 to 2002. He subsequently served as the hospital’s Scientific Director and Executive Vice President before becoming President and Chief Executive Officer, a position he held from 2004 to 2014.
During his career at St. Jude, Dr. Evans held the St. Jude Endowed Chair of Pharmacogenomics and conducted research focused on the pharmacodynamics and pharmacogenomics of anticancer agents in children. His contributions earned him three consecutive NIH MERIT Awards.
Dr. Evans has authored more than 450 publications and received several prestigious national honors, including the 2009 Pediatric Oncology Award from ASCO, the 2009 Team Science Prize from AACR, the 2012 Remington Medal, and the 2016 Parker Medal.
A member of the National Academy of Medicine and the German National Academy of Sciences, Dr. Evans is also a Professor Emeritus at the University of Tennessee Colleges of Medicine and Pharmacy. He previously served on the Board of Directors of Accredo Health.
